Intercure Ltd
INCR
Company Profile
Business description
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
Contact
85 Medinat ha-Yehudim Street
Herzliya4676670
ISRT: +972 774605012
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
320
Stocks News & Analysis
stocks
ASX retail share remains cheap despite weaker earnings
Weaker profit result drives cut to fair value yet shares remain undervalued.
stocks
AI isn’t an economic moat killer, but it will disrupt industries
How we’re rethinking companies’ competitive advantages in an AI-first world.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,745.00 | 13.50 | -0.15% |
| CAC 40 | 7,846.55 | 102.63 | 1.33% |
| DAX 40 | 22,957.08 | 320.17 | 1.41% |
| Dow JONES (US) | 46,429.49 | 305.43 | 0.66% |
| FTSE 100 | 10,106.84 | 141.68 | 1.42% |
| HKSE | 25,335.95 | 272.24 | 1.09% |
| NASDAQ | 21,929.82 | 167.93 | 0.77% |
| Nikkei 225 | 54,035.88 | 286.26 | 0.53% |
| NZX 50 Index | 13,047.21 | 117.91 | 0.91% |
| S&P 500 | 6,591.90 | 35.53 | 0.54% |
| S&P/ASX 200 | 8,540.80 | 6.20 | -0.07% |
| SSE Composite Index | 3,931.84 | 0.00 | 0.00% |